⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29257541 | 0.83 | — | — | |
| Nitric Acid SCHEMBL7114599 | 0.73 | CA5A (0.50) | — | |
| SCHEMBL8625234 | 0.72 | — | — | |
| SCHEMBL28266038 | 0.72 | — | — | |
| SCHEMBL4938940 | 0.71 | — | — | |
| SCHEMBL66347 | 0.69 | — | — | |
| SCHEMBL9065965 | 0.69 | — | — | |
| SCHEMBL5651338 | 0.69 | — | — | |
| SCHEMBL28862229 | 0.67 | ALDH1A1 (0.58) | — | |
| SCHEMBL5651341 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771350-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170226082-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2017-08-10 | — | — | US | disclosed |
| US-9682957-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170096412-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2017-04-06 | — | — | US | disclosed |
| US-9572802-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY LLC (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160361304-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2016-12-15 | — | — | US | disclosed |
| US-9394275-B2 | Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150274697-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9000173-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140323733-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8816088-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8551978-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130137665-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |